sur Telomir Pharmaceuticals, Inc
Telomir Pharmaceuticals Appoints New Chief Scientific Advisor
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) has appointed Dr. Itzchak Angel as Chief Scientific Advisor. Telomir, a pre-clinical-stage company, focuses on developing treatments for age-related conditions through its lead product candidate, Telomir-1. This small molecule aims to lengthen DNA's protective telomere caps, crucial in the aging process.
Dr. Angel previously served as Head of Pharmacology at Synthelabo (now Sanofi-Aventis), contributing to groundbreaking drugs such as Ambien and Uroxatral. His 40-year career spans neurology, psychiatry, metabolic diseases, and more. At Telomir, he will expedite the development of Telomir-1 towards clinical trials for human and veterinary indications.
Positive preclinical coverage of Telomir-1 has spurred Telomir to pursue Investigational New Animal Drug applications alongside human Investigational New Drug applications. A notable target is progeria, a rare genetic disorder. Telomir-1's potential to elongate telomeres could address this devastating condition.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Telomir Pharmaceuticals, Inc